Long-Term Outcomes in Pericarditis, Polygenic Risk Score and Predicting CVD, Aortic Disease in Children with FBN1-Related Marfan Syndrome

Medical notice: Educational content only. CanduCardio is intended for healthcare professionals and CanduTV for the general public. It does not replace clinical judgment or professional consultation.

CanduAudio

About this episode

More episodes from this podcast

The new ACC Scientific Statement on Exercise Prescription for CV Health, Multimodality Cardiac Imagine, Risk Stratification & CMR, Preventive PCI and CV Risk

Sex Disparities in CV Trials; Left Stellate Ganglion Blocks & CABG; Bifurcation Lesions; Managing Resistant Hypertension

ACC/AHA Joint Perioperative Guidelines; Atenolol and MACE Risk; Yoga and VPCs; DECIPHER and CMR

Whole Grain Intake & CV Health, Talfamidis & Recurrent Cardiovascular Events, Revascularization & Improved Cognition, Coronary Blood Flow in Women

First Medical Contact, CV Toxicity and Antibody-Drug Conjugates, Extreme Heat & Blood Pressure, FinACAF & Lower Risk of ischemic Stroke

CV Subspecialty Training; a Novel Left Atrium Staging Framework; the (IL)-6 Inflammatory Biomarker, HF Risk & Diabetes

Top Five Trials from ESC 26: SINGLE-AF, REBOOT-PARADOX, ViVA, REACT, NOTION-4

M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM.

: M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM.

CAC, CRF & Dementia; Athletes & Arrhythmia; Vutrisaran & Amyloid Burden; NT0proBNP Screening & Heart Failure

Antithrombotic Regimens after Valve-in-Vave TAVR; TAV vs. SAVR Outcomes in Low-Risk Patients; Sex Difference and Delayed Diagnosis on Acoramidis; Lifestyle Intervention and ANOCA

Venous Thromboembolism & Cancer; Influenza Vaccines & AFib; the DAPT-MVD Trial & Cutting PCI in CAD; the AC Expect Consensus Decision Pathway on HFpEF

Age, BMI, & TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial & Tirzepatide.

Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE

Long-Term Outcomes in Pericarditis, Polygenic Risk Score and Predicting CVD, Aortic Disease in Children with FBN1-Related Marfan Syndrome

About this episode

More episodes from this podcast

The new ACC Scientific Statement on Exercise Prescription for CV Health, Multimodality Cardiac Imagine, Risk Stratification & CMR, Preventive PCI and CV Risk

Sex Disparities in CV Trials; Left Stellate Ganglion Blocks & CABG; Bifurcation Lesions; Managing Resistant Hypertension

ACC/AHA Joint Perioperative Guidelines; Atenolol and MACE Risk; Yoga and VPCs; DECIPHER and CMR

Whole Grain Intake & CV Health, Talfamidis & Recurrent Cardiovascular Events, Revascularization & Improved Cognition, Coronary Blood Flow in Women

First Medical Contact, CV Toxicity and Antibody-Drug Conjugates, Extreme Heat & Blood Pressure, FinACAF & Lower Risk of ischemic Stroke

CV Subspecialty Training; a Novel Left Atrium Staging Framework; the (IL)-6 Inflammatory Biomarker, HF Risk & Diabetes

Top Five Trials from ESC 26: SINGLE-AF, REBOOT-PARADOX, ViVA, REACT, NOTION-4

M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM.

: M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM.

CAC, CRF & Dementia; Athletes & Arrhythmia; Vutrisaran & Amyloid Burden; NT0proBNP Screening & Heart Failure

Antithrombotic Regimens after Valve-in-Vave TAVR; TAV vs. SAVR Outcomes in Low-Risk Patients; Sex Difference and Delayed Diagnosis on Acoramidis; Lifestyle Intervention and ANOCA

Venous Thromboembolism & Cancer; Influenza Vaccines & AFib; the DAPT-MVD Trial & Cutting PCI in CAD; the AC Expect Consensus Decision Pathway on HFpEF

Age, BMI, & TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial & Tirzepatide.

Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE